Curatis: Double-digit revenue growth in 2025 and major milestones for corticorelin achieved
Download PDF release →Ad hoc announcement pursuant to Art. 53 LR
Liestal, Switzerland, 24 March 2026: Curatis Holding AG (SIX:CURN, "Curatis") reports business revenues of CHF 10.8m (+5% vs. prior year on a comparable basis*) in fiscal year 2025.
In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG revenues grew by 12% vs. the prior year.
A major milestone was achieved in the development of our lead project, corticorelin, following a successful meeting with the FDA in September 2025. FDA confirmed that a single pivotal Phase 3 study in the US would be sufficient for approval. FDA further confirmed that the study could be initiated without prior Phase 2 data and provided clear guidance on the study design.
In March 2026, Curatis concluded a licensing agreement for corticorelin in Japan with Neupharma Co., Ltd., Tokyo. Neupharma will be responsible for conducting the Phase 3 study and commercialising corticorelin in Japan.
Curatis Holding AG · Weierweg 7, CH-4410 Liestal · SIX: CURN